Sign In
Buy VTRS
$17.56
-0.200 (-1.13%)
At Close: Jul 31, 2026
Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025
09:00am, Wednesday, 01'st Oct 2025
PITTSBURGH , Oct. 1, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) will report third quarter 2025 financial results on Thursday, November 6, 2025. Company executives will host a webcast at 8:30 a.m
Viatris: Indore Plant Could Boost 2026 Numbers
01:16pm, Thursday, 25'th Sep 2025
Viatris continues to struggle with declining sales across all regions, with Q2-2025 net sales down 7% year over year. VTRS's Indore plant issues have significantly impacted results, but a full recover
Insider Watch: 3 CEOs Buying the Dip
12:31pm, Wednesday, 03'rd Sep 2025
Investors closely monitor insider buys, as they can give hints surrounding the long-term picture.
Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer
09:00am, Tuesday, 19'th Aug 2025
PITTSBURGH , Aug. 19, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the appointment of Andrew Enrietti as Chief Administrative and Transformation Offic
Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.
09:29am, Monday, 11'th Aug 2025
Approval is Another Milestone of Viatris' Ability to Successfully Develop Complex Generic Medicines Approval Granted with Competitive Generic Therapy Eligibility for 100mg/5mL and 200mg/10mL Strengths
Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates
12:01pm, Thursday, 07'th Aug 2025
VTRS beats on Q2 estimates with strength in branded drugs and growth in Greater China, lifting shares.
Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript
11:02am, Thursday, 07'th Aug 2025
Viatris Inc. (NASDAQ:VTRS ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Scott Andr
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics
10:36am, Thursday, 07'th Aug 2025
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to
Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise
09:36am, Thursday, 07'th Aug 2025
Drugmaker Viatris beat Wall Street estimates for second-quarter profit and revenue on Thursday, helped by demand for its products in China, sending its shares up nearly 5% in early trading.
Viatris (VTRS) Tops Q2 Earnings and Revenue Estimates
09:06am, Thursday, 07'th Aug 2025
Viatris (VTRS) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.69 per share a year ago.
Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance
06:59am, Thursday, 07'th Aug 2025
Delivers Total Revenues Above Expectations Reflecting the Strength of our Execution and the Resilience of our Diversified Global Business Positive Results From Five Phase 3 Data Readouts This Year Rei
Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
10:16am, Wednesday, 06'th Aug 2025
Get a deeper insight into the potential performance of Viatris (VTRS) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some o
Viatris Announces Quarterly Dividend
06:59am, Tuesday, 05'th Aug 2025
PITTSBURGH , Aug. 5, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on August 4, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued a
Viatris Announces Appointment of David Simmons to the Company's Board of Directors
06:55am, Tuesday, 05'th Aug 2025
PITTSBURGH , Aug. 5, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that David Simmons has been appointed as the newest member of Viatris' Board of Di
Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?
03:11pm, Monday, 04'th Aug 2025
VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.
